LMY 921
Alternative Names: LMY-921Latest Information Update: 12 Oct 2022
At a glance
- Originator Luminary Therapeutics
- Class Antineoplastics; CAR-T cell therapies; Gene therapies; Immunotherapies
- Mechanism of Action Immunologic cytotoxicity; T lymphocyte replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Preclinical Mantle-cell lymphoma
Most Recent Events
- 12 Oct 2022 Preclinical trials in Mantle-cell lymphoma in USA (Parenteral) before October 2022 (Luminary Therapeutics pipeline, October 2022)
- 23 Feb 2021 Luminary Therapeutics in-licenses TcBuster™ technology from Bio-Techne
- 03 Dec 2020 Case Western Reserve University has patent protection for BAFF target for use in CAR-T constructs in USA